Liver involvement in cystic fibrosis

被引：12

作者：

Brigman C. ^{[1
]}

Feranchak A. ^{[1
]}

机构：

[1] Department of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, TX 75390

来源：

Current Treatment Options in Gastroenterology | 2006年 / 9卷 / 6期

关键词：

Cystic Fibrosis; Octreotide; Portal Hypertension; Transjugular Intrahepatic Portosystemic Shunt; Esophageal Varix;

D O I：

10.1007/s11938-006-0005-8

中图分类号：

学科分类号：

摘要：

The hepatobiliary manifestations of cystic fibrosis (CF) encompass a broad clinical spectrum, from mild steatosis, associated with poor nutrition, to multilobular cirrhosis and the complications of portal hypertension. The factor(s) responsible for the development and progression of liver disease in a subset of patients with CF are unknown. Liver disease can be silent and progressive, manifesting only with complications associated with cirrhosis and portal hypertension. Clinical evaluation for detecting and monitoring the progression of liver disease includes the following: physical examination of the liver, biochemical tests of Liver function and injury, and radiological imaging with abdominal ultrasonography. Careful monitoring should take place in all patients with CF, as currently, there are no sensitive and/or specific historical or biochemical markers to predict who is at risk for the development of Liver disease. Current treatment options for CF-associated liver disease are very Limited. The bile acid ursodeoxycholic acid may improve biochemical parameters of liver disease, but its tong-term efficacy in preventing the progression of liver disease in CF is unproven. Treatment therefore rests on optimizing nutritional status; correcting fat-soluble vitamin, essential fatty acid, and other mineral deficiencies; and treating complications of end-stage liver disease, such as pruritis, ascites, and portal hypertension. Copyright © 2006 by Current Science Inc.

引用

页码：484 / 496

页数：12

共 62 条

[1]

Dodge J.A., Morison S., Lewis P.A., Et al., Incidence, population, and survival of cystic fibrosis in the UK, 1968-95, Arch Dis Child, 77, pp. 493-496, (1997)

[2]

Kosorok M.R., Wei W.H., Farrell P.M., The incidence of cystic fibrosis, Stat Med, 15, pp. 449-462, (1996)

[3]

Riordan J.R., Rommens J.M., Kerem B., Et al., Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA, Science, 245, pp. 1066-1073, (1989)

[4]

Gaskin K.J., Waters D.L., de Silva M., Et al., Liver disease and bile duct stenosis in cystic fibrosis, Lancet, 335, (1990)

[5]

Linblad A., Glaumann H., Strandvik B., Natural history of liver disease in cystic fibrosis, Hepatology, 30, pp. 1151-1158, (1999)

[6]

Colombo C., Battezzati P.M., Crosignani A., Et al., Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome, Hepatology, 36, pp. 1374-1382, (2002)

[7]

Cohn J., Strong T., Picciotto M., Et al., Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells, Gastroenterology, 105, pp. 1857-1864, (1993)

[8]

Sharma R., Florea V.G., Bolger A.P., Et al., Wasting as an independent predictor of mortality in patients with cystic fibrosis, Thorax, 56, pp. 746-750, (2001)

[9]

Littlewood J.M., An overview of the management of cystic fibrosis, J R Soc Med, 79, SUPPL. 12, pp. 55-63, (1986)

[10]

Ramsey B.W., Farrell P.M., Pencharz P.B., Et al., Nutritional assessment and management in cystic fibrosis: A consensus report, Am J Clin Nutr, 55, pp. 108-116, (1992)

← 1 2 3 4 5 6 7 →